Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
EDITORIAL
Michael A Perelman
No abstract text is available yet for this article.
April 12, 2024: International Journal of Impotence Research
#2
JOURNAL ARTICLE
S Giatti, L Cioffi, S Diviccaro, R Piazza, R C Melcangi
PURPOSE: As reported in patients treated for androgenetic alopecia with finasteride (i.e., a blocker of the enzyme 5 alpha-reductase) and in an animal model, side effects affecting sexual, psychiatric, neurological, and physical domains, may occur during the treatment and persist with drug suspension. The etiopathogenesis of these side effects has been poorly explored. Therefore, we performed a genome-wide analysis of finasteride effects in the brain of adult male rat. METHODS: Animals were treated (i...
March 17, 2024: Journal of Endocrinological Investigation
#3
JOURNAL ARTICLE
Silvia Giatti, Silvia Diviccaro, Lucia Cioffi, Roberto Cosimo Melcangi
Post-finasteride syndrome and post-SSRI sexual dysfunction, are two poorly explored clinical conditions in which men treated for androgenetic alopecia with finasteride or for depression with SSRI antidepressants show persistent side effects despite drug suspension (e.g., sexual dysfunction, psychological complaints, sleep disorders). Because of some similarities in the symptoms, common pathological mechanisms are proposed here. Indeed, as discussed, clinical studies and preclinical data obtained so far suggest an important role for brain modulators (i...
November 20, 2023: Frontiers in Neuroendocrinology
#4
REVIEW
Herman H J Leliefeld, Frans M J Debruyne, Yakov Reisman
Finasteride and dutasteride, synthetic 5α-reductase inhibitors (5ARIs) are recommended in many guidelines for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms and alopecia despite a variety of side effects like sexual, neurological, psychiatric, endocrinological, metabolic and ophthalmological dysfunctions and the increased incidence of high grade prostate cancer. The sexual side effects are common during the use of the drug but in a small subgroup of patients, they can persist after stopping the drug...
September 11, 2023: International Journal of Impotence Research
#5
REVIEW
Murat Gül, Mikkel Fode, Ahmet Urkmez, Paolo Capogrosso, Marco Falcone, Selcuk Sarikaya, Ioannis Sokolakis, Afonso Morgado, Andrey Morozov, Maarten Albersen, Giorgio Ivan Russo, Ege Can Serefoglu
Conditions referred to as 'male sexual dysfunctions' usually include erectile dysfunction, ejaculatory disorders and male hypogonadism. However, some less common male sexual disorders exist, which are under-recognized and under-treated, leading to considerable morbidity, with adverse effects on individuals' sexual health and relationships. Such conditions include post-finasteride syndrome, restless genital syndrome, post-orgasmic illness syndrome, post-selective serotonin reuptake inhibitor (SSRI) sexual dysfunction, hard-flaccid syndrome, sleep-related painful erections and post-retinoid sexual dysfunction...
January 2024: Nature Reviews. Urology
#6
JOURNAL ARTICLE
Silvia Diviccaro, Monika Herian, Lucia Cioffi, Matteo Audano, Nico Mitro, Donatella Caruso, Silvia Giatti, Roberto Cosimo Melcangi
Despite its efficacy for treating androgenetic alopecia, finasteride, an inhibitor of 5α-reductase (i.e., the enzyme converting testosterone, T, into dihydrotestosterone, DHT), is associated with several side effects including sexual dysfunction (e.g., erectile dysfunction). These side effects may persist after drug suspension, inducing the so-called post-finasteride syndrome (PFS). The effects of subchronic treatment with finasteride (i.e., 20 days) and its withdrawal (i.e., 1 month) in rat corpus cavernosum have been explored here...
August 24, 2023: Andrology
#7
JOURNAL ARTICLE
Haidar Al Saffar, Jennifer Xu, Jonathan S O'Brien, Brian D Kelly, Declan G Murphy, Nathan Lawrentschuk
UNLABELLED: Finasteride competitively inhibits 5α-reductase (5-AR) isoenzymes, which blocks dihydrotestosterone (DHT) production, thereby reducing DHT. Finasteride is used in the management of benign prostatic hyperplasia (BPH) and androgenic alopecia. Amid patient reports of suicidal ideation (SI), the Post Finasteride Syndrome advocacy group has petitioned for either a stop to selling of the drug or advertisement of stronger warnings. The US Food and Drug Administration recently added SI to the adverse effects listed for finasteride...
June 2023: European urology open science
#8
REVIEW
Bodie Chislett, David Chen, Marlon L Perera, Eric Chung, Damien Bolton, Liang G Qu
5-alpha reductase inhibitors (5-ARIs) are commonly used and widely available, with benefits observed from their effect on androgen signalling. Their effect relies on the inhibition of the 5-alpha reductase enzyme which aids in the conversion of testosterone to dihydrotestosterone. 5-ARIs have increasing clinical relevance outside of benign prostatic hyperplasia (BPH). Such development requires clinicians to have an updated review to guide clinical practices. This review details the pharmacology and mechanisms of action for 5-ARIs and how this relates to multiple clinical indications...
March 31, 2023: Translational Andrology and Urology
#9
Xiaogang Li, Ye Guo, Yi Lu, Haolong Li, Songxin Yan, Hongjun Li, Yongzhe Li
BACKGROUND: Finasteride is widely used in the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia (AGA). Post-finasteride syndrome (PFS) is a spectrum of persistent symptoms reported by some patients after treatment with finasteride for androgenetic alopecia. These patients show many abnormal clinical manifestations, including psychological disorders (depression and anxiety, among others) and sexual dysfunction. However, there is insufficient research on the persistent severe side effects in young male patients with PFS, and the underlying mechanism of PFS has not been fully elucidated...
October 2022: Translational Andrology and Urology
#10
JOURNAL ARTICLE
Silvia Diviccaro, Silvia Giatti, Lucia Cioffi, Eva Falvo, Monika Herian, Donatella Caruso, Roberto Cosimo Melcangi
The treatment with finasteride (i.e., an inhibitor of 5α-reductase) may be associated with different side effects (i.e., depression, anxiety, cognitive impairment and sexual dysfunction) inducing the so-called post finasteride syndrome (PFS). Moreover, previous observations in PFS patients and an experimental model showed alterations in gut microbiota populations, suggesting an inflammatory environment. To confirm this hypothesis, we have explored the effect of chronic treatment with finasteride (i.e., for 20 days) and its withdrawal (i...
October 26, 2022: Biomolecules
#11
JOURNAL ARTICLE
Kian Asanad, Tamir Sholklapper, Mary K Samplaski, Giovanni E Cacciamani
Prior literature has suggested that finasteride may negatively impact men's sexual health. In 2011, the Food and Drug Administration (FDA) provided a warning on finasteride drug labels to incorporate sexual side effects such as reduced libido and erectile dysfunction. We aimed to evaluate global online interest in finasteride sexual side effects, their penetrance and variation, and how they compared overtime. We also aimed to evaluate the influence of the FDA label warnings on web-based searches for finasteride side effects...
September 13, 2022: International Journal of Impotence Research
#12
REVIEW
Pedro Romero Pérez
INTRODUCTION AND OBJECTIVES: Post-finasteride syndrome (PFS) is a little known adverse effect of 5α-reductase inhibitor (5-ARI) drugs used in benign prostatic hyperplasia (BPH) and androgenetic alopecia. Five articles on the syndrome have been published in Spain, although no review has been published.The objectives of this article are to review the world literature, including the Spanish literature. MATERIAL AND METHODS: A retrospective review on post-finasteride syndrome was performed between 2011 and 2020...
June 2022: Archivos Españoles de Urología
#13
JOURNAL ARTICLE
Nicolò Schifano, Paolo Capogrosso, Luca Boeri, Giuseppe Fallara, Stefania Chiappini, Matthew Rewhorn, Omer Onur Cakir, Hannah Harvey, Fabio Castiglione, Hussain M Alnajjar, Asif Muneer, Federico Deho', Fabrizio Schifano, Francesco Montorsi, Andrea Salonia
A limited number of studies have described patients on finasteride showing findings which were consistent with Peyronie's disease (PD). We aimed to detect a pharmacovigilance signal of possible association between finasteride and PD-related clinical features. The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried to identify the ten drugs which were associated the most with the adverse drug reactions (ADRs) recorded as "penile curvature" and/or "Peyronie's disease"...
May 5, 2022: International Journal of Impotence Research
#14
REVIEW
Sandeep Suresh Sattur, Indu Sandeep Sattur
Pattern hair loss (PHL) is a condition that worsens with time and the only way it can be slowed down is with pharmacological intervention. Pharmacological treatments for PHL, from an evidenced-based perspective with respect to safety and efficacy, are limited to only two drugs, minoxidil and finasteride. However, there are a host of drugs being used, off-label with limited evidence. This article attempts to review the literature on this topic, and the authors add to this, with their experience of over two decades on incorporating pharmacologic treatments along with hair transplantation in their management of PHL...
October 2021: Indian Journal of Plastic Surgery: Official Publication of the Association of Plastic Surgeons of India
#15
JOURNAL ARTICLE
Patrick Low, Kevin D Li, Nizar Hakam, Alexander Bell, Behzad Abbasi, Jason Lui, Nathan M Shaw, Benjamin N Breyer
BACKGROUND: 5α-reductase inhibitors are commonly prescribed medications with multiple side effects used in the treatment of male pattern hair loss and benign prostatic hyperplasia. These side effects including "post-finasteride syndrome" may result in lawsuits. OBJECTIVES: To characterize lawsuits involving the adverse side effects of 5α-reductase inhibitor to better understand drivers of litigation and outcomes. METHODS: Legal cases were queried from Nexis Uni using the search terms "5-alpha reductase inhibitor" as well as specific agents "finasteride," "dutasteride" in combination with "malpractice," "negligence," "damage," "loss," "side effect," and "complication...
March 2022: Andrology
#16
EDITORIAL
Ralph M Trüeb, Maria Fernanda Reis Gavazzoni Dias, Hudson Dutra Rezende
No abstract text is available yet for this article.
November 2021: Skin Appendage Disorders
#17
JOURNAL ARTICLE
David Healy, Audrey Bahrick, Maarten Bak, Angelo Barbato, Rocco Salvatore Calabrò, Barbara M Chubak, Fiammetta Cosci, Antonei B Csoka, Barbara D'Avanzo, Silvia Diviccaro, Silvia Giatti, Irwin Goldstein, Heiko Graf, Wayne J G Hellstrom, Michael S Irwig, Emmanuele A Jannini, Paddy K C Janssen, Mohit Khera, Manoj Therayil Kumar, Joanna Le Noury, Michał Lew-Starowicz, David E J Linden, Celine Lüning, Dee Mangin, Roberto Cosimo Melcangi, Omar Walid Muquebil Ali Al Shaban Rodríguez, Jalesh N Panicker, Arianna Patacchini, Amy M Pearlman, Caroline F Pukall, Sanjana Raj, Yacov Reisman, Rachel S Rubin, Rudy Schreiber, Stuart Shipko, Barbora Vašečková, Ahad Waraich
BACKGROUND: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin. OBJECTIVE: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD)...
2022: International Journal of Risk & Safety in Medicine
#18
REVIEW
Thiraphat Saengmearnuparp, Bannakij Lojanapiwat, Nipon Chattipakorn, Siriporn Chattipakorn
Recent literature connects 5-alpha reductase inhibitors (5-ARIs) with neuropsychiatric adverse effects. Several clinical studies have indicated that former 5-ARIs users had a higher incidence of depressive symptoms and neuropsychiatric side effects than non-users. However, the underlying mechanisms involved in the depression in former 5-ARIs patients, a condition known as "post finasteride syndrome (PFS)", are not thoroughly understood. This review aims to summarize and discuss the association between 5-ARIs and depression as well as possible mechanisms...
November 2021: Biomedicine & Pharmacotherapy
#19
REVIEW
A K Gupta, M Venkataraman, M Talukder, M A Bamimore
BACKGROUND AND OBJECTIVES: Finasteride 1 mg/day is indicated for androgen-dependent conditions such as male androgenetic alopecia (AGA). METHODS: The literature is comprehensively summarized on the pharmacodynamics, pharmacokinetics, mechanism of action, and metabolism of finasteride. Pairwise and network meta-analyses were performed to assess the efficacy of finasteride reported in clinical trials. The adverse events profile is described along with the post-marketing reports...
June 2022: Journal of Dermatological Treatment
#20
JOURNAL ARTICLE
Skyler Howell, Weitao Song, Alexander Pastuszak, Mohit Khera
BACKGROUND: An organic etiology underpinning post-finasteride syndrome, a constellation of persistent sexual, neuropsychiatric, and somatic symptoms reported by men exposed to 5-alpha-reductase inhibitors (5ARIs), is debated. Persistent changes in neurosteroid levels or androgen receptor expression have been implicated. AIM: To determine whether differences in gene expression, especially in relevant biologic pathways, exist between patients reporting post-finasteride syndrome symptoms and healthy controls...
September 2021: Journal of Sexual Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
